Simplify Logo

Full-Time

Associate Scientist / Senior Associate Scientist

LNP Process Science

Posted on 6/8/2024

Generation Bio

Generation Bio

51-200 employees

Developing genetic medicines with non-viral delivery

Hardware
Biotechnology
Healthcare

Junior

Cambridge, MA, USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • Minimum of B.S. with a minimum of 2 years experience or an M.S. degree in Chemical Engineering, Pharmaceutics, Materials Science, Polymer Chemistry, Chemistry, Biochemistry, or related field.
  • Experience in drug product formulation and process development of nanoparticles. Specific experience with lipid nanoparticles is preferred.
  • Familiarity with process engineering principles and Design of Experiment (DOE) statistical tools.
  • Demonstrated ability to operate in a fast-paced environment.
  • Excellent communication, collaboration, interpersonal and organizational skills.
  • Results-driven with excellent attention to details.
  • Proven ability to effectively plan and organize complex work activities and prioritize task completion to meet schedules and deadlines.
Responsibilities
  • Design and execute experiments to optimize the drug product formulation process using both nucleotides and lipid nanoparticles (LNPs).
  • Support the production and characterization of LNP formulations targeted for research and pre-clinical programs.
  • Collaborate with cross-functional departments to aid in the development and evaluation of LNP formulations for product delivery.
  • Understand processes to enable representative LNP production at all scales.
  • Maintain thorough electronic lab notebooks and ensure completion of all appropriate protocols and documentation.
  • Communicate findings internally and present results broadly in cross-functional meetings.

Generation Bio

Company Stage

IPO

Total Funding

$536.4M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-11%

1 year growth

-23%

2 year growth

-20%
Simplify Jobs

Simplify's Take

What believers are saying

  • The development of iqDNA and ctLNP platforms positions Generation Bio at the forefront of genetic medicine innovation, potentially leading to breakthrough treatments for rare and prevalent diseases.
  • Strategic reorganization and cost-saving measures extend the company's cash runway into the second half of 2027, providing financial stability and continued investment in R&D.
  • High-profile presentations at conferences and collaborations with industry leaders like Moderna enhance the company's visibility and credibility in the biotech sector.

What critics are saying

  • The 40% workforce reduction as part of the strategic reorganization could impact employee morale and productivity.
  • Dependence on successful integration and advancement of iqDNA and ctLNP platforms carries inherent risks if the technologies do not perform as expected in clinical settings.

What makes Generation Bio unique

  • Generation Bio's focus on non-viral genetic medicines using proprietary immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms sets it apart from traditional gene therapy companies.
  • Their scalable capsid-free manufacturing process, utilizing rapid enzymatic synthesis (RES), offers a unique advantage in producing genetic medicines efficiently.
  • The strategic collaboration with Moderna highlights Generation Bio's innovative approach and industry recognition.
INACTIVE